✦ LIBER ✦

Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia

✍ Scribed by Cortes, J E; Egorin, M J; Guilhot, F; Molimard, M; Mahon, F-X

Book ID: 109887122
Publisher: Nature Publishing Group
Year: 2009
Tongue: English
Weight: 167 KB
Volume: 23
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2009.88

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Correlation Between Imatinib Pharmacokin

Correlation Between Imatinib Pharmacokinetics and Clinical Response in Japanese Patients With Chronic-Phase Chronic Myeloid Leukemia

✍ Takahashi, N; Wakita, H; Miura, M; Scott, S A; Nishii, K; Masuko, M; Sakai, M; M 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 148 KB

Has the time come for induction and main

Has the time come for induction and maintenance imatinib therapy in chronic myeloid leukemia?

✍ Edgar Faber 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML) and there is no doubt about its role in the first-line therapy of this myeloproliferation. However, there is continuing discussion about how to dose it. Routinely, avoiding single doses lower than 300 mg and continuous daily

Correlations between imatinib pharmacoki

Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): An emerging role for drug blood level testing?

✍ Margaret von Mehren; Nicolas Widmer 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 836 KB

Imatinib trough plasma levels do not cor

Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting

✍ Edgar Faber; David Friedecký; Kateřina Mičová; Šárka Rožmanová; Martina Divoká; 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 227 KB

Cytogenetic and molecular responses to s

Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels

✍ Donna L. Forrest; Shannon Trainor; Ryan R. Brinkman; Michael J. Barnett; Donna E 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Brain natriuretic peptide level as marke

Brain natriuretic peptide level as marker of cardiac function in imatinib—Treated chronic myeloid leukemia patients: No evidence of cardiotoxicity of imatinib therapy

✍ Mario Tiribelli; Antonio Colatutto; Luciana Marin; Giuseppe Barbina; Ugo Qualizz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 2 views